多囊卵巢综合征患者GnRH激动剂预处理与否的人工周期冻胚移植妊娠结局与成本效果比较:一项随机对照试验
该开放标签随机对照试验纳入343例拟行人工周期冻胚移植的多囊卵巢综合征患者,比较GnRH激动剂预处理组(n=172)与对照组(n=171)。意向性分析显示两组活产率无显著差异(49.4% vs 53.8%,绝对率差-4.4%,95%CI -10.8%至2.0%,P=0.45),但预处理组每周期直接费用及每活产直接费用均显著更高。结论认为GnRH激动剂预处理未改善妊娠结局且增加患者费用。
要点
- PCOS患者AC-FET前GnRH-a预处理未提高活产率(49.4% vs 53.8%,P=0.45)。
- 预处理组每FET周期直接费用中位数显著高于对照组(7799.2 vs 4438.9 RMB,P<0.001)。
- 预处理组每活产直接费用中位数亦显著更高(15663.1 vs 8189.9 RMB,P<0.001)。
核心结论
- 对于接受人工周期冻胚移植的PCOS女性,GnRH激动剂预处理不改善妊娠结局,但显著增加患者费用。
研究设计与样本
- 开放标签随机对照试验,在大学附属医院生殖中心进行,共纳入343例24-40岁、拟行AC-FET且移植不超过2枚囊胚的PCOS女性。
- 预处理组172例接受GnRH-a预处理,对照组171例未接受,分析遵循意向性治疗原则。
主要发现
- 意向性分析活产率预处理组85/172(49.4%) vs 对照组92/171(53.8%),绝对率差-4.4%,95%CI -10.8%至2.0%,P=0.45。
- 着床率、临床妊娠率及早期妊娠丢失率两组间亦无差异。
- 每FET周期直接费用中位数预处理组7799.2 RMB vs 对照组4438.9 RMB,OR=1.9,95%CI 1.2-3.4,P<0.001。
- 每活产直接费用中位数预处理组15663.1 RMB vs 对照组8189.9 RMB,OR=1.9,95%CI 1.2-3.8,P<0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the live birth rate and cost effectiveness of artificial cycle-prepared frozen embryo transfer (AC-FET) with or without GnRH agonist (GnRH-a) pretreatment for women with polycystic ovary syndrome (PCOS). DESIGN: Open-label, randomised, controlled trial. SETTING: Reproductive centre of a university-affiliated hospital. SAMPLE: A total of 343 women with PCOS, aged 24-40 years, scheduled for AC-FET and receiving no more than two blastocysts. METHODS: The pretreatment group (n = 172) received GnRH-a pretreatment and the control group (n = 171) did not. Analysis followed the intention-to-treat (ITT) principle. MAIN OUTCOME MEASURES: The primary outcome measure was live birth rate. Secondary outcome measures included clinical pregnancy rate, implantation rate, early pregnancy loss rate and direct treatment costs per FET cycle. RESULTS: Among the 343 women randomised, 330 (96.2%) underwent embryo transfer and 328 (95.6%) completed the protocols. Live birth rate according to ITT did not differ between the pretreatment and control groups [85/172 (49.4%) versus 92/171 (53.8%), absolute rate difference -4.4%, 95% CI -10.8% to 2.0% (P = 0.45). Implantation rate, clinical pregnancy rate and early pregnancy loss rate also did not differ between groups, but median direct cost per FET cycle was significantly higher in the pretreatment group (7799.2 versus 4438.9 RMB, OR = 1.9, 95%CI 1.2-3.4, P < 0.001). Median direct cost per live birth was also significantly higher in the pretreatment group (15663.1 versus 8189.9 RMB, odds ratio [OR] = 1.9, 95% CI 1.2-3.8, P < 0.001). CONCLUSIONS: Pretreatment with GnRH-a does not improve pregnancy outcomes for women with PCOS receiving AC-FET, but significantly increases patient cost. TWEETABLE ABSTRACT: For women with PCOS, artificial cycle-prepared FET with GnRH agonist pretreatment provides no pregnancy outcome benefit but incurs higher cost.
引用
- Luo L, Chen M, Wen Y, et al. Pregnancy outcome and cost-effectiveness comparisons of artificial cycle-prepared frozen embryo transfer with or without GnRH agonist pretreatment for polycystic ovary syndrome: a randomised controlled trial. BJOG. 2020. PMID: 32783367. doi:10.1111/1471-0528.16461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。